Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5554697 | 0.97 | CHEK1 (0.56) | CHEK1GAAMAPTGFERCDK2AP1 | |
| SCHEMBL5550837 | 0.87 | CHEK1 (0.79) | CHEK1CDK2AP1 | |
| SCHEMBL1563670 | 0.86 | USP30 (0.68) | CHEK1GAAMAPTGFERALOX15 | |
| SCHEMBL5556420 | 0.85 | CHEK1 (0.65) | CHEK1CDK2AP1 | |
| SCHEMBL1564584 | 0.84 | USP30 (0.64) | CHEK1GAAMAPTGFERALOX15 | |
| SCHEMBL5554681 | 0.84 | CHEK1 (0.76) | CHEK1CDK2AP1 | |
| SCHEMBL4214970 | 0.81 | CHEK1 (0.57) | CHEK1CDK2AP1ALOX15 | |
| SCHEMBL27677400 | 0.81 | CHEK1 (0.54) | CHEK1GAAMAPTGFERCDK2AP1 | |
| SCHEMBL27677393 | 0.81 | CHEK1 (0.54) | CHEK1GAAMAPTGFERCDK2AP1 | |
| SCHEMBL1127833 | 0.78 | CHEK1 (0.51) | CHEK1MAPTGFERCDK2AP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1732920-A2 | THIOPHENE DERIVATIVES AS CHK 1 INHIBITORS | AstraZeneca AB (SE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005066163-A2 | THIOPHENE DERIVATIVES AS CHK 1 INIHIBITORS | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010556-A1 | Thiophene derivatives as chk 1 inhibitors | CHEK1, CHKA, CHEK2 | CHEK1 1/4885GAA 2518/4885MAPT 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.